Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 21:10:1956.
doi: 10.3389/fmicb.2019.01956. eCollection 2019.

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues

Paul W Denton  1 , Ole S Søgaard  2   3 , Martin Tolstrup  2   3
Affiliations
Review

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues

Paul W Denton et al. Front Microbiol. .

Abstract

HIV reservoirs persist in infected individuals despite combination antiretroviral therapy and can be identified in secondary lymphoid tissues, in intestinal tissues, in the central nervous system as well as in blood. Clinical trials have begun to explore effects of small molecule interventions to perturb the latent viral infection, but only limited information is available regarding the impacts of HIV cure-related clinical interventions on viral reservoirs found in tissues. Of the 14 HIV cure-related clinical trials since 2012 that have evaluated the effects of small molecule interventions in vivo, four trials have examined the impacts of the interventions in peripheral blood as well as other tissues that harbor persistent HIV. The additional tissues examined include cerebral spinal fluid, intestines and lymph nodes. We provide a comparison contrast analyses of the data across anatomical compartments tested in these studies to reveal where peripheral blood analyses reflect outcomes in other tissues as well as where the data reveal differences between tissue outcomes. We also summarize the current knowledge on these topics and highlight key open questions that need to be addressed experimentally to move the HIV cure research field closer to the development of an intervention strategy capable of eliciting long-term antiretroviral free remission of HIV disease.

Keywords: HIV cure; interventional clinical trials; latency; tissues; viral persistence.

PubMed Disclaimer

References

    1. Anton P. A., Mitsuyasu R. T., Deeks S. G., Scadden D. T., Wagner B., Huang C., et al. (2003). Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 17 53–63. 10.1097/00002030-200301030-00008 - DOI - PubMed
    1. Archin N. M., Bateson R., Tripathy M. K., Crooks A. M., Yang K. H., Dahl N. P., et al. (2014). HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. J. Infect. Dis. 210 728–735. 10.1093/infdis/jiu155 - DOI - PMC - PubMed
    1. Archin N. M., Kirchherr J. L., Sung J. A., Clutton G., Sholtis K., Xu Y., et al. (2017). Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J. Clin. Invest. 127 3126–3135. 10.1172/JCI92684 - DOI - PMC - PubMed
    1. Archin N. M., Liberty A. L., Kashuba A. D., Choudhary S. K., Kuruc J. D., Crooks A. M., et al. (2012). Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487 482–485. 10.1038/nature11286 - DOI - PMC - PubMed
    1. Banga R., Procopio F. A., Noto A., Pollakis G., Cavassini M., Ohmiti K., et al. (2016). PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat. Med. 22 754–761. 10.1038/nm.4113 - DOI - PubMed

LinkOut - more resources